PSEN2

Across TCGA pan-cancer cohorts, PSEN2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSEN2 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PSEN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PSEN2 expression acts as an unfavorable survival marker.

STAD, HNSC, and ESCA are the cancer types where PSEN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.219	0.680	<.001	45	view →
HNSC	OS	Median	III,IV	0.057	0.746	<.001	24	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSEN2–STAD (OS)

Open the STAD breakdown →